The Italian ISAC Study Group: Maria Beatrice Bilò3, Matteo Bonini4, Maria Chiara Braschi3, Elisabetta Di Leo8, Claudia Fantini8, Filippo Fassio5, Claudia Gramiccioni4, Carla Lombardo6, Alessia Marcomini2, Erika Rela2, Anna Maria Riccio1, Anthi Rogkakou1, Oliviero Rossi5, Elisa Villa1.
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy
Article first published online: 28 JUL 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 68, Issue 8, pages 1029–1033, August 2013
How to Cite
and the Italian ISAC Study Group The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy 2013; 68: 1029–1033., , , , , , , , , ,
Edited by: Reto Crameri
- Issue published online: 23 AUG 2013
- Article first published online: 28 JUL 2013
- Manuscript Accepted: 30 APR 2013
- IgE assay;
- ISAC microarray;
- respiratory allergy;
- skin prick test
The IgE response is directed against specific components from an allergenic source. The traditional diagnostic methods use whole extracts, containing allergenic, nonallergenic and cross-reactive molecules. This may pose diagnostic challenges in polysensitized patients. Microarray techniques detect specific IgE against multiple molecules, but their value in term of additional information and economic saving has not been yet defined.
We assessed the additional diagnostic information provided by an allergen microarray in a large population of polysensitized subjects.
In this multicentre study, allergists were required to carefully record diagnosis and treatment of consecutive patients referred for asthma/rhinitis, using the standard methodology (history, skin prick test, IgE assay). Then, a microarray allergen assay was carried out. Clinicians were required to review their diagnosis/treatment according to microarray results.
318 allergic patients (30% reporting also nonrespiratory symptoms) and 91 controls were enrolled. The clinicians reported at least one additional information from the microarray in about 60% of patients, this resulting in therapeutic adjustments. In 66% of patients IgE to pan-allergens were detectable, being this clinically relevant in 38% of patients with polysensitization to pollens.
Microarray IgE assay represents an advancement in allergy diagnosis, as a third-level approach in polysensitized subjects, when the traditional diagnosis may be problematic.